Skip to main content

Hydralazine injection Shortage

Last Updated: May 18, 2023
Status: Current

Products Affected - Description
    • Hydralazine injection, Akorn, 20 mg/mL, 1 mL vial, 10 count, NDC 17478-0934-10 - discontinued
    • Hydralazine injection, Mylan Institutional (Viatris), 20 mg/mL, 1 mL vial, 25 count, NDC 67457-0291-01 - discontinued
Reason for the Shortage
    • Akorn ceased operations in February 2023.
    • American Regent has hydralazine injection available.
    • Eugia has hydralazine injection available.
    • Fresenius Kabi has hydralazine injection available.
    • Hikma has hydralazine injection available.
    • Viatris discontinued hydralazine injection in April 2023.
    • X-Gen is not currently manufacturing hydralazine injection.
Available Products
    • Hydralazine injection, American Regent, 20 mg/mL, 1 mL vial, 25 count, NDC 00517-0901-25
    • Hydralazine injection, Eugia US, 20 mg/mL, 1 mL vial, 25 count, NDC 55150-0400-25
    • Hydralazine injection, Fresenius Kabi, 20 mg/mL, 1 mL vial, 25 count, NDC 63323-0614-01
    • Hydralazine injection, Hikma, 20 mg/mL, 1 mL vial, 25 count, NDC 00641-6231-25

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated May 18, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created June 4, 2018 by Anthony Trovato, PharmD, BCPS. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer